Title: Using Exenatide Twice Daily or Insulin in Clinical Practice: Results from CHOICE
Authors: Mathieu, Chantal ×
Ostenson, Claes-Göran
Matthaei, Stephan
Reaney, Matthew
Krarup, Thure
Guerci, Bruno
Kiljański, Jacek
Salaun-Martin, Carole
Sapin, Hélène
Theodorakis, Michael #
Issue Date: Dec-2013
Publisher: Springer Healthcare Ltd.
Series Title: Diabetes Therapy vol:4 issue:2 pages:285-308
Abstract: CHOICE (CHanges to treatment and Outcomes in patients with type 2 diabetes initiating InjeCtablE therapy; NCT00635492) assessed, as its primary objective, the time to a 'significant treatment change' (defined within this paper) after patients with type 2 diabetes mellitus initiated their first injectable, glucose-lowering therapy [exenatide twice daily (BID) or insulin] in clinical practice in six European countries and evaluated outcomes during the study.
ISSN: 1869-6961
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Clinical and Experimental Endocrinology
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science